| Species |
Human |
| Protein Construction |
| His |
PSMA/FOLH1 (Lys44-Ala750)_x000D_
Accession # Q04609-1 |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized PSMA/FOLH1, His, Human at 2μg/ml (100μl/Well) on the plate can bind AntiPSMA Antibody, hFc Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
80.6 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 90-110 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Prostate-specific membrane antigen (PSMA) is an enzyme that in humans is encoded by the FOLH1 (folate hydrolase 1) gene, also known as Glutamate carboxypeptidase II (GCPII). Human PSMA is highly expressed in the prostate, roughly a hundred times greater than in most other tissues. In some prostate cancers, PSMA is the second-most upregulated gene product, with an 8- to 12-fold increase over levels in noncancerous prostate cells. |
| Synonyms |
GCP2; PSMA; PSMAFGCP; FGCP; Folate hydrolase 1; FOLHNAALADase I; GCPII; GCPIImGCP; NAALAD1; NAALADase I; NAALAdase; FOLH1; GIG27; PSM; FOLH; mGCP |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
